Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report

Nivolumab, an antibody against human programmed cell death 1 (PD-1), enhances pre-existing immune responses and has antitumor activity. However, it may also cause undesirable immune-related adverse events (irAEs), such as anti-PD-1-related colitis. In addition, Nivolumab can worsen pre-existing auto...

Descripción completa

Detalles Bibliográficos
Autores principales: Hijikata, Yasuki, Matsubara, Yasuo, Ota, Yasunori, Lim, Lay Ahyoung, Tani, Kenzaburo, Hirata, Yoshihiro, Yotsuyanagi, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205527/
https://www.ncbi.nlm.nih.gov/pubmed/32009094
http://dx.doi.org/10.2169/internalmedicine.3901-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205527/
https://www.ncbi.nlm.nih.gov/pubmed/32009094
http://dx.doi.org/10.2169/internalmedicine.3901-19

Ejemplares similares